OverviewSuggest Edit

Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. The Company bases its approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. Loxo Oncology is developing a pipeline of highly selective drugs that inhibit oncogenic drivers in cancer.

TypePublic
Founded2013
HQStamford, US
Websiteloxooncology.com

Latest Updates

Employees (est.) (Feb 2019)59(+26%)
Job Openings65
Share Price (Feb 2019)$234.7

Key People/Management at Loxo Oncology

Josh Bilenker

Josh Bilenker

Founder, President & CEO
Nisha Nanda

Nisha Nanda

VP of Development Strategy
Jacob Van Naarden

Jacob Van Naarden

Chief Business Officer
Jennifer Burstein

Jennifer Burstein

VP of Finance
Show more

Loxo Oncology Office Locations

Loxo Oncology has offices in Stamford and South San Francisco
Stamford, US (HQ)
281 Tresser Blvd, 14th Floor
South San Francisco, US
400 Oyster Point Blvd #520
Show all (2)
Report incorrect company information

Loxo Oncology Financials and Metrics

Loxo Oncology Revenue

USD

Net income (Q2, 2018)

(15.3m)

EBIT (Q2, 2018)

(20.5m)

Market capitalization (15-Feb-2019)

7.2b

Closing stock price (15-Feb-2019)

234.7

Cash (30-Jun-2018)

147.7m
Loxo Oncology's current market capitalization is $7.2 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

583.0k10.5m14.9m33.7m

R&D expense

323.0k14.0m58.3m140.0m

Operating expense total

906.0k24.5m73.2m173.7m

EBIT

(152.4m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

2.4m2.6m3.4m3.8m3.7m4.8m6.5m9.7m12.2m27.9m

R&D expense

2.8m3.4m8.4m12.3m14.2m20.2m24.4m64.8m32.0m73.5m

Operating expense total

5.2m5.9m11.8m16.1m17.9m24.9m30.9m74.4m44.2m101.5m

EBIT

(5.8m)(20.5m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

43.9m68.2m30.4m142.0m

Accounts Receivable

1.1b

Current Assets

107.8m156.6m141.8m781.8m

PP&E

12.0k88.0k248.0k912.0k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(20.7m)(35.9m)(72.4m)(148.9m)

Depreciation and Amortization

1.0k17.0k77.0k125.0k

Accounts Payable

18.0k30.0k792.0k2.9m

Cash From Operating Activities

(2.8m)(30.2m)(51.3m)107.8m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(8.1m)(8.8m)(11.6m)(15.9m)(17.7m)(24.5m)(54.9m)(128.2m)(3.6m)(15.3m)

Depreciation and Amortization

21.0k48.0k80.0k80.0k186.0k

Accounts Payable

207.0k285.0k415.0k731.0k758.0k677.0k1.0m192.0k1.1m768.0k1.8m793.0k

Cash From Operating Activities

(26.7m)(50.5m)(113.4m)109.8m74.8m
USDY, 2018

Financial Leverage

1.8 x
Show all financial metrics
Report incorrect company information

Loxo Oncology Online and Social Media Presence

Embed Graph
Report incorrect company information

Loxo Oncology News and Updates

Lilly Completes Acquisition of Loxo Oncology

INDIANAPOLIS, Feb. 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (NASDAQ:LOXO). The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines through the addition of ...

Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology

INDIANAPOLIS, Feb. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2018. $ in millions, except per share data Fourth Quarter % Full Year % 2018 2017 Change 2018 2017 Change Revenue $ 6,438.6 $ 6,160.7 5% $ ...

Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction

INDIANAPOLIS and STAMFORD, CT, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the…

WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests of LOXO Shareholders

NEW YORK, Jan. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Loxo Oncology, Inc. ("LOXO" or the "Company") (NASDAQ: LOXO) in connection with the proposed acquisition of the Company by Eli...

UPDATE 5-Lilly makes $8 bln bet on drugs for rare cancers with Loxo Oncology buy

Eli Lilly said on Monday it will buy Loxo Oncology Inc for $8 billion, an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in the drugmaker's 143-year history.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Loxo Oncology, Inc.

NEW YORK, Jan. 7, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Loxo Oncology, Inc. (NASDAQ: LOXO) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY). Stockholders ...
Show more
Report incorrect company information

Loxo Oncology Frequently Asked Questions

  • When was Loxo Oncology founded?

    Loxo Oncology was founded in 2013.

  • Who are Loxo Oncology key executives?

    Loxo Oncology's key executives are Josh Bilenker, Nisha Nanda and Jacob Van Naarden.

  • How many employees does Loxo Oncology have?

    Loxo Oncology has 59 employees.

  • Who are Loxo Oncology competitors?

    Competitors of Loxo Oncology include LGC Biosearch Technologies, Fate Therapeutics and Parexel International.

  • Where is Loxo Oncology headquarters?

    Loxo Oncology headquarters is located at 281 Tresser Blvd, 14th Floor, Stamford.

  • Where are Loxo Oncology offices?

    Loxo Oncology has offices in Stamford and South San Francisco.

  • How many offices does Loxo Oncology have?

    Loxo Oncology has 2 offices.